CGRP Education & Research Forum
Already a member? Become a member Register
youtubeLinkedIn
News

Erenumab

Erenumab

In May 2018, Aimovig (erenumab) became the first CGRP monoclonal antibody to be approved for the prevention of migraine in adults. Approval was supported by data including results of the Phase 3 STRIVE and ARISE studies in episodic migraine and the results of a large Phase 2 study in chronic migraine. Erenumab was further investigated in the Phase 3b LIBERTY study of patients with migraine who had failed on 2-4 previous preventive therapies.


Download slideset »


« back to Slides